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Leuven Kulak, Department of Public Health and Primary Care, University of Leuven, Kortrijk, BelgiumMesenchymal stromal cells (MSCs) exhibit anti-
inﬂammatory and immune-regulatory properties, and
preclinical studies suggest a potential beneﬁt in solid organ
transplantation. We report on the 1-year follow-up of an
open-label phase I-II trial of a single infusion of third-party
MSC post-kidney transplantation, in addition to standard
immunosuppression. Ten kidney transplant recipients from
deceased donors received third-party bone marrow MSCs
(w2 3 106/kg) on day 3 ± 2 post-transplant and were
compared to 10 concurrent controls. No adverse effects
were noted at MSC injection. One participant with a history
of cardiac disease had a non-ST-elevation myocardial
infarction approximately 3 hours after MSC infusion.
Incidences of opportunistic infections and acute rejection
were similar. At day 7 post-transplant, estimated
glomerular ﬁltration rate (eGFR) in MSC-treated recipients
reached 48.6 ml/min/1.73m2, compared to 32.5 ml/min/
1.73m2 in controls and 29.3 ml/min/1.73m2 in our overall
cohort of kidney transplant recipients. No difference in
eGFR was found at 1 year. MSC-treated recipients showed
increased frequencies of regulatory T cells at day 30, with
no signiﬁcant change in B cell frequencies compared to
concurrent controls. Four MSC-treated participants
developed antibodies against MSC or shared kidney-MSC
HLA, with only 1 with MFI >1500. A single infusion of third-
party MSC following kidney transplantation appears to be
safe, with one cardiac event of unclear relationship to the
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immunization against MSC, remain to be studied.
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K idney transplantation (KTx) is the best treatment ofend-stage renal failure. Although immunosuppressivedrugs lower the incidence of acute rejection (AR),
long-term graft and patient survivals are hampered by the
adverse effects of chronic immunosuppression.1 Novel strate-
gies are therefore required. Cellular therapy has elicited
considerable interest in solid organ transplantation (SOT).2–4
It aims at preventing and/or treating ischemia/reperfusion injury
and AR as well as inducing tolerance and minimization of
immunosuppression.5,6 Several types of cells are currently inves-
tigated, including mesenchymal stromal cells (MSCs).7 MSCs
represent a heterogeneous population of ﬁbroblast-like adult
multipotent cells that can be isolated from various tissues.8–10
Anti-inﬂammatory and immune-regulatory properties of
MSCs of both innate and adaptive immune systems have been
described in several in vitro and in vivo models.11–15 Further-
more, MSCs display tissue repair function.15
On the basis of convincing preclinical studies,16–21 MSCs
represent a promising tool in SOT,6,22–25 which prompted
clinical trials using MSCs as (i) induction26 or mainte-
nance27,28 therapy, (ii) additional therapy to standard
immunosuppression,29–32 and (iii) treatment of (sub)clinical
rejection33 or interstitial ﬁbrosis and tubular atrophy.34 Most
studies focused on safety and feasibility.24 The main safety
concerns of MSC-based therapy include infusion toxicity and
over-immunosuppression.6 In the case of allogeneic cells,
MSC immunogenicity needs to be addressed. The693
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationadministration of allogeneic MSCs (allo-MSCs) has been
safely achieved in various nontransplant conditions,35 espe-
cially in graft-versus-host disease.36 Still, the MSC donor-
speciﬁc immune response in kidney transplant recipients
(KTRs) is unknown. In vitro and in vivo observations have
documented cellular and humoral responses after MSC
administration.35,37–39 In KTx, 2 clinical trials used allo-MSCs
obtained from the corresponding kidney donors28,40 and 1
from third-party donors41 but the immunization against
MSCs was not evaluated. Third-party MSCs, that is, geneti-
cally unrelated to graft recipients or donors, might offer ad-
vantages, such as (i) prompt availability in the case of
deceased donor transplant program and (ii) selection of
healthy donors. However, the potential rejection of allo-MSCs
may change their properties, induce an immune response
deleterious to the host and/or the graft, and favor the pro-
duction of donor-speciﬁc antibodies (DSAs).42,43
The present study was designed to evaluate the safety and
tolerability of a single i.v. administration of third-party bone
marrow MSCs in 10 KTRs under standard immunosuppres-
sion on day 3 after successful KTx. The primary end points
concerned the adverse effects of MSC infusion as well as in-
fectious and malignant complications at 1 year. The second-
ary end points included the effect of MSCs on graft outcomes
and immunity as well as the occurrence of anti-MSC-DSAs.
MSC-treated patients were compared with 10 KTRs simul-
taneously recruited and characterized. In addition, they were
statistically compared with the whole cohort of patients who
were transplanted in our center during the study period and
who fulﬁlled the inclusion criteria. Such an analysis based on
our prospective database was meant to provide us with a
representative rate of KTx-related events.
RESULTS
Clinical and biological features of kidney donors and
recipients
Twenty patients were recruited in MSC (n ¼ 10) and control
(n ¼ 10) groups between October 2013 and May 2016. In
parallel, 179 KTRs fulﬁlling the study criteria were transplanted
(Figure 1). No difference was detected between MSC and
control groups with regard to baseline characteristics, except
for body mass index (lower in the MSC group than in the
control group; P < 0.05) and warm ischemia time (longer in
the MSC group than in the whole cohort; P < 0.05) (Table 1).
Primary end points
Toxicity related to MSC injection. On day 3 (days 2–5) after
KTx, patients were infused with 2.4  106 MSCs/kg (data are
median [P25-P75]) (2.0  106 –2.6  106 MSCs/kg) in a
median perfusion volume of 333 ml (314–462 ml). The me-
dian duration of infusion was 17 minutes (P25–P75, 13–22
minutes). No signiﬁcant variations in vital parameters or sign
of allergy were noted at the time of and immediately after MSC
injection (Table 2). One patient with ischemic heart disease
(Supplementary Figure S1, patient 6) had non–ST-elevation694myocardial infarction w3 hours after MSC infusion in the
context of postoperative anemia (hemoglobin level, 9 g/dl).
Infectious complications. The incidence of opportunistic
infections was not different between MSC and control groups
(Table 3). Two MSC-treated patients (1 donor status (D)þ/
recipient status (R) and 1 Dþ/Rþ; Supplementary
Figure S1, patients 1 and 7) developed asymptomatic cyto-
megalovirus (CMV) (re)activation versus 1 control (1 D/
Rþ; Supplementary Figure S2, patient 9). In addition, 3
MSC-treated patients (1 Dþ/R, 1 D/Rþ, and 1 Dþ/Rþ;
Supplementary Figure S1, patients 3, 5, and 9) suffered from
CMV syndrome/disease during 1-year follow-up. No CMV
disease was recorded in controls. In the whole cohort, 22% of
KTRs developed CMV viremia, and 13% had CMV disease.
In the MSC group, polyoma BK viremia was noted in 3 pa-
tients (Supplementary Figure S1, patients 5, 8, and 9) versus
4 in controls (Supplementary Figure S2, patients 2, 4, 6, and
8) and 13% in the whole cohort, resulting in 1 biopsy-proven
BK nephropathy in the MSC group (Supplementary
Figure S1, patient 5) versus 2 in the control group
(Supplementary Figure S2, patients 2 and 4) and 4% in the
whole cohort. Finally, 1 MSC-treated patient (Supplementary
Figure S1, patient 5) and 1 patient in the whole cohort
developed pneumocystis pneumonia. Overall, the number of
opportunistic infections was 9 events in 6 MSC-treated pa-
tients, 5 in 5 controls, and 65 in 60 KTRs of the whole
cohort.
Uncontrolled proliferation/cancers. One MSC-treated pa-
tient (Supplementary Figure S1, patient 10) presented a
recurrence of condyloma on day 62. No benign or malignant
tumors was recorded in the 10 controls. Benign tumors were
identiﬁed in 6 patients from the whole cohort—4 colonic
adenomas, 1 condyloma, and 1 dermal neuroﬁbroma—at a
median time of 176 days after KTx (P25–P75, 111–316 days).
Other severe adverse events. Cardiac events included 1
non–ST-elevation myocardial infarctionw3 hours after MSC
infusion, 1 ST-elevation myocardial infarction at day 286, and
1 pacemaker implantation for atrioventricular block at day 55
(Supplementary Table S1). Hospital admissions motivated by
graft dysfunction included 3 per-cause biopsies (AR at day
330, borderline rejection at day 233, and polyoma BK ne-
phropathy at day 265, respectively; Supplementary Figure S1,
patients 2, 3, and 5) and 1 graft revascularization at day 340 in
the MSC group (Supplementary Figure S1, patient 3).
Secondary end points
Patient and graft survivals. All patients and kidney re-
cipients in both MSC and control groups survived at month
12 after KTx. At day 286, 1 MSC-treated patient required
temporary hemodialysis in the context of sepsis, type B aortic
dissection, and ST-elevation myocardial infarction
(Supplementary Figure S1, 5). Kidney graft function recov-
ered w4 weeks after admission. In the whole cohort, 1-year
graft and patient survivals reached 95.5% and 97.8%,
respectively.Kidney International (2019) 95, 693–707
Figure 1 | Design of the study. Analysis 1 refers to comparisons between the 10 MSC-treated vs. the 10 MSC-non-treated patients, whereas
analysis 2 refers to comparisons between the 10 MSC-treated patients and the whole KTR cohort. DBD, donor after brain death; DCD, donor
after circulatory death; EBV, Epstein-Barr virus; HCV, hepatitis C virus; KTR, kidney transplant recipient; KTx, kidney transplantation; MSC,
mesenchymal stromal cell; PNF, primary nonfunction; PRA, panel-reactive antibody.
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a lKidney graft outcomes. Renal graft function. On day 2, the
estimated glomerular ﬁltration rate (eGFR) was comparable
in all groups: (data are median [P25-P75]) 21.9 ml/min per
1.73 m2 (12.0–27.3 ml/min per 1.73 m2) in the MSC group,
19.8 ml/min per 1.73 m2 (10.0–23.9 ml/min per 1.73 m2) in
the control group (P¼ 0.63), and 14.6 ml/min per 1.73 m2 (9.4–
23.9 ml/min per 1.73 m2) in the whole cohort (P¼ 0.24). At day
7, eGFR was signiﬁcantly higher in MSC-treated KTRs (48.6 ml/
min per 1.73 m2 [36.6–56.6 ml/min per 1.73 m2]) than in the
whole cohort (29.3 ml/min per 1.73 m2 [13.4–46.6 ml/min per
1.73 m2]; P < 0.05), with a similar nonsigniﬁcant trend for
controls (32.5 ml/min per 1.73 m2 [26.6–43.3 ml/min per 1.73
m2]; P ¼ 0.07). In all groups, eGFR steeply increases, reaching a
plateau around day 30. No difference in eGFR slopes was
observed among groups. At month 12, eGFR was similar in all
groups (Figure 2).
AR. At day 330, 1 MSC-treated patient had a
biopsy-proven T-cell–mediated AR (Banff type 1B)Kidney International (2019) 95, 693–707(Supplementary Figure S1, patient 2). The patient was
treated by pulses of methylprednisolone, with a rapid and
sustained improvement in eGFR. No control patient
developed AR. Among the whole cohort, 7% of KTRs
showed biopsy-proven AR, with 75% cellular AR, 17%
humoral AR, and 8% mixed AR, at a median time of 31
days after KTx (Table 4).
Immunosuppressive regimen. At month 12, 30% of MSC-
treated patients were free of corticosteroids as compared with
60% of controls and 39% of the whole cohort. Ten percent of
patients in each group achieved transient corticosteroid
withdrawal over 1-year follow-up, but corticosteroids had to
be resumed (Table 4). Reasons for corticosteroid maintenance
in the MSC group were (i) nonoptimal trough levels of cal-
cineurin inhibitor (n ¼ 1), (ii) decrease in other immuno-
suppressive drugs because of polyoma BK viremia (n ¼ 2) or
hematological complication (n ¼ 1), (iii) borderline rejection
(n ¼ 2), and (iv) no surveillance biopsy because of sustained695
Table 1 | Baseline characteristics
Characteristic MSC group (n [ 10) Control group (n [ 10) P1 Whole cohort (N [ 179) P2
Recipients
Age at Tx (yr) 63 (54–67) 64 (51.5–68.7) 0.97 56.7 (46.7–64.7) 0.11
Sex: male/female 7/3 4/6 0.37 118/61 >0.99
BMI (kg/m2) 25.0 (21.6–27.4) 29.1 (27.2–33.2) 0.03 26.0 (22.6–30.1) 0.36
Dialysis vintage (d) 295 (103–943) 411 (295–689) 0.62 581 (281–957) 0.32
Cause of CKD
Diabetic nephropathy 0 1 16
Glomerulonephritis 2 1 37
Polycystic nephropathy 0 3 32
Vascular nephropathy 1 0 9
Interstitial nephritis/APN 1 0 16
Others 2 3 26
Unknown 4 2 43
CDC PRA max
<5%/5%–84%/$85%
9/1/0 9/1/0 – 158/21/0 –
Kidney donors
Age (yr) 52 (47–57) 50 (42–54) 0.52 47 (36–56) 0.29
Sex: male/female 3/7 3/7 – 95/84 0.20
BMI (kg/m2) 21.6 (19.5–26.1) 25.3 (21.5–28.3) 0.13 25.1 (22.9–27.8) 0.03
DBD/DCD 7/3 8/2 >0.99 123/56 >0.99
KTx
CMV status
1: Dþ/Rþ; 2: Dþ/R; 3: D/Rþ; 4: D/R
3/3/3/1 2/2/5/1 0.82 52/38/52/37 0.83
CIT (min) 716 (504–814) 586 (274–833) 0.47 761 (520–931) 0.53
WIT (min) 45 (40–57) 44 (26–48) 0.29 38 (33–46) 0.02
HLA mismatches
Total (0/1/2/3/4/5) 0/1/2/3/4/0 1/0/2/5/2/0 – 12/14/39/69/44/1 0.87
A (0/1/2) 1/6/3 3/7/0 0.13 56/101/22 0.16
B (0/1/2) 2/6/2 2/5/3 0.86 26/108/45 0.86
DR (0/1/2) 2/8/0 1/9/0 – 47/127/5 0.77
Early graft function, immediate/slow/delayed 8/2/0 7/3/0 – 97/49/33 0.20
Induction
CNI, CsA/FK/none 0/10/0 0/10/0 – 3/176/0 –
Antimetabolite, MMF/MPA/Aza/none 10/0/0/0 10/0/0/0 – 175/1/0/3 –
Basiliximab, yes/no 10/0 10/0 – 170/9 –
mTOR inhibitor, yes/no 0/10 0/10 – 3/176 –
APN, acute pyelonephritis; Aza, azathioprine; BMI, body mass index; CDC PRA, complement-dependent cytotoxicity panel-reactive antibody; CIT, cold ischemia time; CKD,
chronic kidney disease; CMV, cytomegalovirus; CNI, calcineurin inhibitor; CsA, cyclosporine A; D, donor status; DBD, donor after brain death; DCD, donor after circulatory death;
FK, tacrolimus; HLA, human leukocyte antigen; KTx, kidney transplantation; MMF, mycophenolate mofetil; MPA, mycophenolic acid; MSC, mesenchymal stromal cell; mTOR,
mammalian target of rapamycin; R, recipient status; Tx, transplantation; WIT, warm ischemia time.
Data are expressed as median (P25–P75) for continuous variables and as number for categorical variables. Hypothesis testing was performed using the Fisher exact test for
categorical variables and the nonparametric Mann-Whitney U test for continuous variables. P1 refers to comparisons between MSC and control groups, whereas P2 refers to
comparisons between the MSC group and the whole cohort.
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationantiplatelet therapy (n ¼ 1). Mycophenolate mofetil therapy
was transiently interrupted for hematological complications
in 30% of MSC-treated patients, 20% of controls, and 16% of
the whole cohort (Supplementary Table S2).
Recipient’s immune function. Peripheral blood lymphocyte
counts. No difference was found in the occurrence of leuko-
penia, lymphopenia, or neutropenia among groups
(Supplementary Table S2). Quantitative analyses of white
blood cells showed signiﬁcant differences between MSC andTable 2 | Comparison of vital parameters before, during, and aft
Parameter Before MSC infusion
Temperature (C) 36 (36–36.6)
Mean arterial pressure (mm Hg) 101 (95–108)
Heart rate (per min) 79 (74–90)
SpO2 (%) 95 (94–97)
MSC, mesenchymal stromal cell; SpO2, peripheral capillary oxygen saturation.
Data are expressed as median (P25–P75). P values were calculated using the Friedman
696control groups at day 180 (7980 cells/ml [6168–9038 cells/ml]
vs. 4785 cells/ml [3858–6415 cells/ml]; P < 0.05)
(Supplementary Table S3). Peripheral blood lymphocyte
phenotyping showed an increased number of CD3CD56þ
cells in the MSC group compared with the control group at
day 30 (Figure 3). At later stages, similar levels of
CD3CD56þ cells were observed. No difference in other cell
subsets could be detected on day 30, 90, 180, or 365
(Supplementary Table S3).er MSC infusion
After 15 min End of MSC infusion P
36.05 (35.6–36.6) 36.05 (35.6–36.6) 0.79
105.2 (101.8–112.5) 108 (103.7–114.1) 0.07
81 (72–88) 80 (72–91) 0.71
94 (93–96) 95 (91–97) 0.71
test.
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Table 3 | Opportunistic infections
Variable MSC group (n [ 10) Control group (n [ 10) P1 Whole cohort (N [ 179) P2
Overall (no. of patients) 9 (6) 5 (5) 65 (60)
CMV
CMV DNAemia n (%) 4 (40) 1 (10) 0.30 40 (22) 0.25
Time from KTx (d) 172 (95–255) 258 – 102 (58–178) 0.15
CMV disease n (%) 3 (30) 0 (0) 0.21 24 (13) 0.16
Time from KTx (d) 263 (113–298) – 80 (58–144) 0.05
Polyomavirus BK
Urine alone n (%) 4 (40) 1 (10) 0.30 42 (23) 0.26
Time from KTx (d) 91 (89–98) 83 – 92 (82-104) >0.99
Plasma n (%) 3 (30) 4 (40) >0.99 24 (13) 0.16
Time from KTx (d) 186 (83–187) 93 (89–182) >0.99 105 (87-163) 0.73
Tissue n (%) 1 (10) 2 (20) >0.99 8 (4) 0.39
Time from KTx (d) 265 157 (96–218) – 164 (89–281) –
Pneumocystis n (%) 1 (10) 0 >0.99 1 (0.6) 0.10
Time from KTx (d) 298 – 176 –
CMV, cytomegalovirus; KTx, kidney transplantation.
Data are expressed as median (P25–P75) for continuous variables or as number for categorical variables. Signiﬁcant infections in toto include CMV DNAemia or disease,
polyoma BK viremia or nephropathy, and pneumocystis infection. Hypothesis testing was performed using the Fisher exact test for categorical variables and the
nonparametric Mann-Whitney U test for continuous variables. P1 refers to comparisons between MSC and control groups, whereas P2 refers to comparisons between the MSC
group and the whole cohort.
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a lCD4 phenotyping. An increased percentage of regulatory T
cells (Tregs) among CD4þ cells was observed at day 30 in
MSC-treated KTRs compared with controls (all data are mean
 SD unless otherwise noted) (4.3%  0.98% vs. 3%  1.1%;
P < 0.05) (Figure 4). The absolute number of Tregs was not
signiﬁcantly different at day 30 (43.5  23.9 cells/ml vs. 36.3 
23.5 cells/ml; P ¼ 0.48). From day 0 to day 180, there was a
signiﬁcant decrease in Treg percentage in controls (4.1% 
0.7% vs. 2%  0.7%; P < 0.01). Such a decrease was not
observed in the MSC group (4.9%  3.6% vs. 3.2%  1.9%).
This resulted in a higher number of Tregs at day 180 in MSC-
treated KTRs than in control KTRs (29.5  15.7 cells/ml vs.
15.1  7.3 cells/ml; P < 0.05). When a Treg phenotype was
analyzed further, we observed a decreased proportion of
resting (CD45RAHLA-DR) Tregs and a trend toward an
increased proportion of activated effector (CD45RAHLA-
DRþ) Tregs at day 180 in MSC-treated patients compared
with controls (52.2%  12.7% and 27.4%  16.6% vs. 67.4%
 13.7% and 16.4%  7.6%; P < 0.05 and P ¼ 0.075,
respectively). These ﬁndings were consistent with the
increased expression of Ki-67 and phosphorylated signal
transducer and activator of transcription 5 in Tregs at day 30
in MSC-treated patients compared with controls (3.4% 
2.9% and 1056  304 vs. 0.8%  0.3% and 520  92; P <
0.01 and P < 0.001, respectively). The HLA-DR mean ﬂuo-
rescence intensity (MFI) of DRþ Tregs was signiﬁcantly
higher in MSC-treated KTRs than in controls at day 30 (P <
0.05) (Figure 4). No difference was found in the renal count
of CD3þ T cells or the Foxp3þ/CD3þ ratio on 3-month graft
biopsies from MSC-treated patients versus controls (Table 4).
CD19 phenotyping and serum levels of Igs. B-cell frequencies
in MSC-treated patients were similar to controls at each time
point during 1-year follow-up. Focusing on MSC-treated
patients, we observed a signiﬁcant decrease in CD19þ cell
percentage from day 30 to day 180 (all data are mean  SD
unless otherwise noted) (21.7%  9.4% vs. 8.8%  5.9%;Kidney International (2019) 95, 693–707P < 0.05) and from day 30 to day 365 (21.7%  9.4% vs.
11.2%  7.2%; P < 0.05) as well as a signiﬁcant decrease in
the percentage of CD27IgDþ naive B cells from day 30 to
day 365 (68%  18.6% vs. 58.9%  21.6%; P < 0.01) and
from day 180 to day 365 (64.2%  21% vs. 58.9%  21.6%;
P < 0.05) (Figure 5). With regard to the serum levels of Igs, no
signiﬁcant difference was found for IgG and IgM between MSC
and control groups at each time point during follow-up. The
levels of IgAwere signiﬁcantly higher in theMSC group already in
the pretransplant period (data are median [P25-P75]) (2.5 g/l
[2.1–3.6 g/l] vs. 1.7 g/l [1.3–2.8 g/l] in controls; P< 0.05), which
hampered any interpretation (Figure 6).
Anti-MSC donor human leukocyte antigen antibodies. Third-
party MSCs were randomly assigned to KTRs, with no human
leukocyte antigen (HLA) matching to kidney recipients or
kidney donors. In 5 patients, HLA mismatches were shared
between MSC and kidney donors (Supplementary Table S4).
De novo MSC-DSAs with MFI > 1500 were detected in 1 pa-
tient from month 6. Two additional de novo MSC-DSAs and 1
shared kidney/MSC-DSAs were “positive” according to the
manufacturer’s recommendations (Table 5). In addition, 1
MSC-treated patient developed de novo class I kidney DSAs,
with a median corrected MFI of 320 (P25–P75, 196–1342), at
months 1, 3, and 6 (but not at month 12). None of the pre-
transplant anti-HLA antibodies corresponded to MSC-DSAs
(Supplementary Tables S5 and S6).
DISCUSSION
No safety signal has been described thus far after systemic MSC
infusion in humans, except for transient fever.44 Although lung
entrapment of MSCs was reported in rodents,45 chest pain or
blood deoxygenation has not been observed in humans, except
in 1 anecdotal case.46 Here, 1 patient with ischemic heart disease
developed non–ST-elevation myocardial infarction w3 hours
after MSC infusion in the context of postoperative anemia.
Thrombogenicity is a constitutive feature of MSCs,47,48 which697
Figure 2 | Evolution of glomerular ﬁltration rate (eGFR) after
kidney transplantation. eGFR was estimated using the Modiﬁcation
of Diet in Renal Disease equation. eGFR was signiﬁcantly higher at day
7 in the mesenchymal stromal cell (MSC) group than in the whole
cohort, with a similar nonsigniﬁcant trend for the control group. eGFR
at 12 months after kidney transplantation was similar in all groups.
Statistical analyses were performed using the Mann-Whitney U test.
Repeated measures of eGFR were evaluated using linear mixed
models with ﬁxed effects on group, day, age, and sex and patient as a
random effect. P1 refers to comparisons between MSC and control
groups, whereas P2 refers to comparisons between the MSC group
and the whole cohort.
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationmay lead to distal occlusions.49 However, given the incidence of
16% of perioperative myocardial injury in noncardiac surgery,50
the factual role of MSCs in this cardiac event remains debatable.
MSC associated risks of infections and cancers are a major
theoretical concern, especially in the case of chronic immuno-
suppression.51 In the largest study comparing MSCs plus low- or
standard-dose calcineurin inhibitor with anti–interleukin-2 re-
ceptor antibody plus standard-dose calcineurin inhibitor as in-
duction therapy in KTx, Tan et al. reported a signiﬁcantly
decreased risk of opportunistic infections in MSC-treated pa-
tients compared with controls.26 In another trial including 6
KTRs infused with MSCs for AR treatment, Reinders et al. re-
ported 3 opportunistic infections.34 In our trial, CMV viremia
turned positive in 40% of MSC-treated patients compared with
10% in controls and 22% in our global cohort. No difference in
CMV baseline status was noted. Although the median time to
CMV disease reached 263 days in the MSC group, our obser-
vations raise the question of a risk of CMV infection when MSCs
are infused in addition to standard immunosuppression. No
difference was highlighted in polyomavirus BK nephropathy for698which immunosuppressive intensity is a crucial risk factor.52 The
risk of de novomalignancy will require long-term follow-up.53 In
SOT, hemangioma has been reported in 1 KTR 2 months after
MSC infusion.31
Most clinical studies in SOT are based on auto-MSCs.
Several limitations with autologous cells exist: (i) the difﬁ-
culty to collect and grow auto-MSCs in sufﬁciency, (ii) the
time constraints for auto-MSC expansion in acute conditions,
and (iii) the alteration of intrinsic properties of auto-MSCs in
sick and/or elderly patients.54 These limitations may prompt
the use of allo-MSCs. MSCs express low levels of major his-
tocompatibility complex (MHC) I and lack MHC II or cos-
timulatory molecules, such as CD40, B7-1, or B7-2.55,56 These
in vitro characterizations led to the hypothesis of an immune-
privileged status of MSCs. Allo-MSCs have been administered
safely in nontransplant patients, with no immunological
complications.35,36 Still, MSCs are regarded as IFNg-regulated
nonprofessional antigen-presenting cells with upregulation of
both MHC I and MHC II complexes.38 In rodents, MSCs
induce speciﬁc antidonor responses.37,39,57,58 In our study, de
novo MSC-DSAs with MFI > 1500 was detected in only 1
patient. Given its transient expression and the high degree of
MSC mismatches, the clinical relevance of this immunization
is uncertain. Moreover, a dual effect may be speculated in
allo-MSC therapy. On the one hand, inducing antibodies
against alloantigens may lead to sensitization and accelerated
decline of kidney graft5,59 and may hamper access to kidney
retransplantation. On the other hand, protolerogenic effects
of donor antigen-bearing allo-MSCs, with desensitization to
donor antigens, have been suggested.60 Our 12-month follow-
up is in line with Lohan’s conclusion that the formation of
alloantibodies may not be as signiﬁcant as originally
hypothesized.43 However, the long-term implications of MSC-
DSAs remain unknown, alongside the tolerability and efﬁcacy
of single or repeated administration of allo-MSCs.43 Our B-cell
phenotyping shows that MSC infusion is particularly associ-
ated with a decrease in the percentage of naive B-cell subset, as
previously suggested.61 Further investigations are required to test
whether such a differential B-cell phenotyping signiﬁcantly affects
the humoral response after KTx.62–64 No difference between
MSC-treated and control patients was observedwith regard to the
subset of IgMþCD27-CD24þCD38high transitional B cells (which
have been linked to tolerance65,66), plasmablasts, and memory B
cells over 1-year follow-up. This is in line with similar Ig levels in
both groups. Two ongoing trials (1 using third-party MSCs for
tolerance induction in deceased donor KTRs [ClinicalTrials.gov
identiﬁer: NCT02565459] and 1 using third-party MSCs at
25 to 26 weeks after KTx [ClinicalTrials.gov identiﬁer:
NCT02387151]67) will further assess the risk of allo-MSC im-
munization in SOT.
Treg lymphocytes correspond to a subpopulation of CD4þ
T cells and are critical for peripheral tolerance.68 MSCs favor
CD4þ T-cell differentiation into Tregs.69–73 MSC-induced
expansion of donor-speciﬁc Tregs was associated with toler-
ance and prolongation of graft survival in a mouse model of
semi-allogeneic heart transplantation.74 Here, MSCKidney International (2019) 95, 693–707
Table 4 | Kidney allograft outcomes over 1-yr follow-up
Outcome MSC group (n [ 10) Control group (n [ 10) P1 Whole cohort (N [ 179) P2
Patient survival (%) 100 100 – 97.8 0.63
Graft survival (%) 100 100 – 95.5 0.50
Surveillance biopsy
CD3þ T cells/HPF 6.3 (4.7–34.7) 118 (6.8–304) 0.09
Foxp3/CD3þ T cells 0.02 (0.002–0.06) 0.02 (0.001–0.04) 0.95
Per-cause biopsy
Acute rejection 1 0 – 12 –
Cellular/humoral/both 1/0/0 – 9/2/1 –
Time from Tx (d) 330 – 31 (9–95) –
Immunosuppressive treatment
over 1-yr follow-up (%)
CNI: CsA/FK/none 0/100/0 0/100/0 – 6/89/1 0.69
Antimetabolite, MMF/MPA/Aza/none 100/0/0/0 70/10/10/10 0.32 66/13/4/12 0.22
mTOR inhibitor 0 0 – 4 >0.99
Corticosteroid withdrawal
Sustained 30 60 39
Transient 10 10 0.37 7 0.78
Neither 60 30 49
Aza, azathioprine; CNI, calcineurin inhibitor; CsA, cyclosporine A; FK, tacrolimus; HPF, high power ﬁeld; MMF, mycophenolate mofetil; MPA, mycophenolic acid; MSC,
mesenchymal stromal cell; mTOR, mammalian target of rapamycin; Tx, transplantation.
Data are expressed as median (P25–P75) for continuous variables unless speciﬁed otherwise. Statistical analyses were performed using the Fisher exact test or the c2 test for
categorical variables and the Mann-Whitney U test for continuous variables. P1 refers to comparisons between MSC and control groups, whereas P2 refers to comparisons
between the MSC group and the whole cohort.
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a ladministration was associated with an increased percentage of
Tregs at day 30 as well as with an increased number of Tregs
and a trend toward an increased proportion ofFigure 3 | Kinetics of T-cell populations in peripheral blood after kid
patients are indicated by dark blue boxes, whereas controls are indicate
(CD3þCD4þ lymphocytes), (b) naive CD4þ T cells (CD4þCD45RAhigh lym
(d) memory CD4þ T cells (CD4þCD45ROþ lymphocytes) at days 0, 30, an
and 75th percentiles) of the distributions (boxes), and whiskers extend
longitudinal statistical analyses between day 30 and the indicated time
between MSC and control groups at the indicated time point. *P # 0.05
Kidney International (2019) 95, 693–707CD45RADRþ Tregs at day 180. The absence of correlation
between blood and kidney Treg frequencies in our series may
come from method limitations and/or the low number ofney transplantation (KTx). Mesenchymal stromal cell (MSC)–treated
d by light blue boxes. Absolute numbers of (a) CD4þ T cells
phocytes), (c) natural killer cells (CD3CD56þ lymphocytes), and
d 180 after kidney transplantation. Plots display the median (25th
to the 10th and 90th percentiles. Arrowheads indicate signiﬁcant
point in the control group. Bold lines represent differences
, ** P # 0.01.
699
Figure 4 | Evolution of regulatory T cells (Tregs) in mesenchymal stromal cell (MSC)–treated versus control kidney transplant
recipients. MSC-treated patients are indicated by dark blue boxes, whereas controls are indicated by light blue boxes. (a) Percentage of Tregs.
(b) Absolute number of Tregs. (c) Treg interleukin-2 signaling (assessed by phosphorylated signal transducer and activator of transcription 5
[pSTAT5] expression levels). (d) Treg proliferation (assessed by Ki-67 expression levels). (e) HLA-DR mean ﬂuorescence intensity (MFI) of acti-
vated effector Tregs. (f) Treg subsets. Tregs were divided into naive HLA-DRCD45RAþ (DR, RAþ), resting HLA-DRCD45RA (DR, RA), and
activated effector HLA-DRþCD45RA (DRþ, RA) cells. Plots display the median (25th and 75th percentiles) of the distributions (boxes), and
whiskers extend to the 10th and 90th percentiles. Arrowheads indicate signiﬁcant longitudinal statistical analyses within MSC or control groups.
Bold lines represent differences between MSC and control groups at the indicated time point. *P # 0.05, **P # 0.01, ***P # 0.001. D0, day 0;
D30, day 30; D180, day 180; D365, day 365; KTx, kidney transplantation.
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationpatients. Two of the previous clinical trials on KTx reported
similar observations as ours.29,31 Another study did not show
changes in the Treg population.27 As a reminder,
CD45RADRþ Tregs show the highest immunosuppressive700activity among Treg subsets.75 Here, the HLA-DR MFI of
DRþ Tregs was signiﬁcantly higher in MSC-treated patients
than in controls. The HLA-DR MFI of CD45RADRþ has
been found to (i) decrease in KTRs with biopsy-proven AR andKidney International (2019) 95, 693–707
Figure 5 | Evolution of B-cell subsets in mesenchymal stromal cell (MSC)–treated versus control kidney transplant recipients. MSC-
treated patients are indicated by dark blue boxes, whereas controls are indicated by light blue boxes. (a) Percentage of CD19þ B cells, (b)
absolute numbers of CD19þ B cells, (c) percentage of naive B cells, (d) marginal zone B cells, (e) transitional B cells, (f) plasmablasts, (g) class
switched memory B cells, (h) class nonswitched memory B cells, and (i) CD21lowCD38low B cells in MSC-treated and control patients at 30, 180,
and 365 days after kidney transplantation (KTx). Plots display the median (25th and 75th percentiles) of the distributions (boxes), and whiskers
extend to the 10th and 90th percentiles. Arrowheads indicate signiﬁcant longitudinal statistical analyses in the MSC group. Bold lines represent
differences between MSC and control groups at the indicated time point. *P # 0.05, **P # 0.01.
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a l(ii) positively correlate with the suppressive activity of the total
Treg cell pool.76,77 Finally, no signiﬁcant difference was observed
with regard to CD45RAþ naive and CD45ROþ memory subsets
of CD4þ T cells. The effect of MSCs onmemory and preactivated
T-cell effectors compared with naive T cells, as well as the dura-
tion of MSC-induced immunomodulation, is incompletely un-
derstood.78,79 Confounding factors, including the type of
immunosuppression or viral infections, complicate the patho-
physiological interpretation of the observations made by us and
others.
A signiﬁcantly higher number of natural killer (NK)
cells was found in MSC-treated patients at day 30. In-
teractions between MSCs and NK cells are complex andKidney International (2019) 95, 693–707controversial.80 MSCs may suppress NK cell proliferation81
and cytotoxicity82 via the release of soluble factors, such as
Indoleamine 2,3- dioxygenase,83 prostaglandin E2,83
insulin-like growth factor b1,84 or Human leukocyte anti-
gen-G5,85 or via direct cell-cell contacts.84 Still, MSCs
themselves may represent a target for activated NK
cells81,83,84,86,87 because MSCs express low levels of class I
MHC molecules.80 Whether the increase in NK cells in
peripheral blood corresponds to (i) a decreased trafﬁcking
of NK cells to the graft, (ii) a deleterious immune response,
or (iii) a long-term beneﬁcial graft outcome as described in
late transplant KTRs88 and tolerant KTRs89 remains un-
clear at this stage.701
Figure 6 | Serum levels of Igs in mesenchymal stromal cell (MSC)–treated versus control kidney transplant recipients. MSC-treated
patients are indicated by dark blue boxes, whereas controls are indicated by light blue boxes. (a) IgG, (b) IgM, (c) IgA levels before kidney
transplantation (KTx) at days 14, 90, 180, and 365. Plots display the median (25th and 75th percentiles) of the distributions (boxes), and whiskers
extend to the 10th and 90th percentiles. Arrowheads indicate signiﬁcant longitudinal statistical analyses between pretransplant values and the
values at indicated time point within MSC or control groups. Bold lines represent differences between MSC and control groups at the indicated
time point. Gray zones depict the normal range. *P # 0.05, **P # 0.01, ***P # 0.001.
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationIn 2011, the ﬁrst administration of auto-MSCs in 2 KTRs
from living-related donors showed a transient deterioration
of renal function w7 to 14 days after MSC infusion at day 7
after KTx, with no sign of AR.31 Kidney biopsy revealed an
inﬁltration of immune cells with C3 deposits. The authors
hypothesized that KTx triggered graft inﬂammation, which
caused MSC recruitment to the graft and favored MSC dif-
ferentiation toward a proinﬂammatory phenotype. Such an
engraftment syndrome was not observed when MSCs were
administered before KTx.30 Furthermore, when MSCs were
used as induction therapy, renal function recovered more
rapidly.26 In our study, eGFR values at day 7 were higher in
MSC-treated patients. One may speculate MSC-induced neph-
roprotection, as suggested by preclinical models.7,15 In a meta-
analysis of preclinical models of AKI, the late (>24 hours)
administration of MSCs after the injury was associated with the
greatest reduction in SCr levels,90 thereby suggesting that the
timing of MSC administration is crucial. Our study was not
powered to assess MSC efﬁcacy in graft recovery. The small
number of MSC-treated deceased donor KTRs limits the
extrapolation of our observations. Still, as underlined by702Bank et al., insights into MSC efﬁcacy in KTx will ﬁrst come
from surrogate short-term end points, including kidney func-
tion and biopsy-proven AR rate.91 Given the safety design of our
study, we used the Modiﬁcation of Diet in Renal Disease
equation92 to estimate and monitor GFR, as recommended by
Kidney Disease: Improving Global Outcomes guidelines.93 Ac-
curate measures of GFR may be recommended for future clinical
trials focusing on MSC efﬁcacy in KTx.
For future clinical trials using third-party MSCs, we
envision 2 main directions: (i) the timing and (ii) the fre-
quency of MSC injection. On the one hand, third-party MSCs
may participate to ischemic preconditioning,11 which may
prompt their administration before KTx29,30 and/or during
organ preservation.94 On the other hand, the repeated
administration of third-party MSCs at distance from KTx
and induction therapy may help sustain MSC-associated
nephroprotection, minimize the pharmacological immu-
nosuppression, and eventually lead to tolerance. Still,
caution is required regarding the putative immunogenicity
of MSCs and the reciprocal interactions between MSCs and
current immunosuppressive drugs.Kidney International (2019) 95, 693–707
Table 5 | Kidney and MSC DSAs in MSC-treated patients over 1-yr follow-up
MSC-treated patient no.
Number of HLA mismatchesa:
–Kidney donor
–MSC donor









































AD-BCR, antigen density background corrected ratio; BCM, background-corrected mean ﬂuorescence intensity; BCR, background corrected ratio; DSA, donor-speciﬁc antibody;
HLA, human leukocyte antigen; MFI, mean ﬂuorescence intensity; MSC, mesenchymal stromal cell; MSC-DSA, mesenchymal stromal cell–donor-speciﬁc antibody.
Anti-HLA antibodies were determined at 1, 3, 6, and 12 mo after kidney transplantation by single antigen bead via Luminex. According to manufacturer’s recommendations
(Immucor Inc.), positive results were considered if 2 of the following 3 criteria were met: BCM > 1500, BCR > 5, or AD-BCR > 5. DSA with MFI > 1500 is underlined and in bold.
aNumber of HLA mismatches; A, B, Cw, DQ, and DR alleles were considered.
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a lMETHODS
Study design
The trial is a monocentric, nonrandomized, controlled, open-
label, phase I-II trial. MSC-treated patients are compared with
(i) 10 eligible KTRs who declined MSC infusion but accepted
supplemental immunological follow-up and (ii) our whole
cohort of KTRs fulﬁlling the inclusion/exclusion criteria who were
transplanted during the study period. The ﬂowchart of the study is
depicted in Figure 1. The inclusion/exclusion criteria for MSC donors
are listed in Supplementary Table S7. Written informed consent was
obtained from all participants. The protocol was approved by the local
ethics committee and by the Federal Agency for Medicines and Health
Products, Brussels, Belgium (EudraCT: 2011-001822-81; Clinical-
Trials.gov identiﬁer: NCT01429038).Kidney International (2019) 95, 693–707MSC isolation and expansion
The protocol of bone marrow MSC isolation and expansion has
recently been detailed in the sister clinical trial testing third-party
MSC infusion in liver transplant recipients32,95 and is described in
Supplementary Information about Patients and Methods, section
MSC isolation and expansion.
MSC infusion
Bone marrow MSCs (1.5 106–3 106 MSCs/kg of body weight) were
centrally infused within 1 hour of thawing. Patients were prepared with
methylprednisolone (2 mg/kg of body weight) and promethazine. The
MSC dose was empirically chosen on the basis of previous clinical trials
in our center using MSCs in nontransplant settings (1 106 to 4  106
MSCs/kg per infusion).95 Given the safety design of the study, MSCs703
c l i n i ca l t r i a l P Erpicum et al.: MSCs in kidney transplantationwere injected only once on day 3  2 to guarantee patients’ stability at
the time of MSC infusion.
KTx
KTR management included antibiotic prophylaxis and CMV/herpes
virus infection prevention. The immunosuppressive regimen was
tacrolimus, mycophenolate mofetil, and corticosteroids associated
with anti–interleukin-2 receptor antibodies on day 0 and day 4. At
month 3, surveillance biopsy was performed: in the absence of
subclinical or borderline rejection, corticosteroid withdrawal was
initiated. Banff classiﬁcation was used.96
Primary and secondary end points
The primary outcome concerns MSC safety at the time of i.v.
administration and at 1-year follow-up. The secondary end points
included (i) the evaluation of patient and graft survivals at month
12, (ii) the effects of MSCs on graft function (eGFR at days 7, 14,
30, 60, 90, 120, 180, 270, and 360), (iii) biopsy-proven AR, (iv)
the feasibility and safety of corticosteroid weaning, (v) KTR im-
mune function, and (vi) occurrence of MSC-DSAs at months 1, 3,
6, and 12.
Peripheral blood lymphocyte immunophenotyping and CD4
and CD19 phenotyping
Peripheral blood mononuclear cells were phenotyped on months 1,
3, 6, and 12 using 4-color ﬂow cytometry after treatment with red
blood cell lysis solution.97 Detailed CD4þ T-cell phenotyping was
performed on days 0, 30, 180, and 365.75 Tregs were deﬁned as
CD4þCD25þCD127lowFoxp3þ lymphocytes, whereas remaining
CD4þ T cells were considered as conventional T cells. Tregs were
divided into naive (CD45RAþHLA-DR), resting (CD45RAHLA-
DR), and activated effector (CD45RAHLA-DRþ) cells
(Supplementary Figures S3 and S4). Ki-67 expression was used to
assess T-cell proliferation, and interleukin-2 signaling was estimated
by quantifying the expression of phosphorylated signal transducer
and activator of transcription 5.75 Detailed B-cell phenotyping was
performed on days 30, 180, and 365. B lymphocytes were deﬁned as
previously described.98 The level of Igs in each group was deter-
mined before KTx and on days 14, 90, 180, and 365.
Immunohistochemistry
Immunostaining against CD3 and Foxp3 was performed on 3-month
surveillance graft biopsies. Cell counting was performed by double-
blind scoring. Parafﬁn-embedded kidney sections underwent im-
munostaining using an automated immunostainer (Ventana Medical
Systems, Tucson, AZ) with antibodies directed against human CD3
(2GV6, Ventana Medical System) and Foxp3 (236A/E7, eBioscience,
San Diego, CA). An ampliﬁcation kit (Ventana Medical Systems) and
a detection system including diaminobenzidine (Ventana Medical
Systems) as a chromogen were used during the automated proced-
ure. Archival lymph node sections were used as positive controls. For
negative controls, the primary antibody was omitted. The mean
number of positive Foxp3þ/CD3þ cells in each patient was classically
counted (original magniﬁcation, 400) in the 3 most cellular
microscopic ﬁelds.
Detection of anti-HLA antibodies
HLA antibody detection and identiﬁcation were performed using
Luminex solid phase antibody detection technology (Immucor Inc.,
Norcross, GA). Sera were tested on days 30, 90, 180, and 365.704Statistical analyses
Statistical analyses were performed using GraphPad Prism (Graph-
Pad Software, San Diego, SA) and SAS 9.4 (SAS Institute Inc., Cary,
NC). The results are presented as median (P25–P75) or mean  SD,
as indicated in text and legends. Statistical assessment was performed
using the nonparametric Mann-Whitney U test. Proportions were
compared using the Fisher exact test. Differences between repeated
measures were evaluated using the Friedman test. Repeated measures
of eGFR were evaluated using linear mixed models with ﬁxed effects
on group, day, age, and sex and patient as a random effect. Survival
curves were calculated using the Kaplan-Meier method. A P value
of <0.05 with a 2-sided test was considered statistically signiﬁcant.DISCLOSURE
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Supplementary Information About Patients and Methods.
Table S1. Noninfectious serious adverse events.
Table S2. Hematological complications.
Table S3. Peripheral blood lymphocyte counts.
Table S4. Human leukocyte antigen mismatches between kidney
recipient, kidney donor, and mesenchymal stromal cell (MSC) donor.
Table S5. Kidney and MSC HLA mismatches and donor-speciﬁc an-
tibodies in MSC-treated patients over 1-yr follow-up.
Table S6. HLA mismatches and DSA follow-up in the control group
over 1-yr follow-up.
Table S7. Inclusion and exclusion criteria for mesenchymal stromal
cell donors.
Figure S1. Individual evolution of mesenchymal stromal cell (MSC)–
treated kidney transplant recipients over 1-year follow-up. CMV,
cytomegalovirus; D2, day 2; D4, day 4; D5, day 5; DSA, donor-speciﬁc
antibody; eGFR, estimated glomerular ﬁltration rate; KTx, kidney
transplantation; MSC-DSA, mesenchymal stromal cell–donor-speciﬁcKidney International (2019) 95, 693–707
P Erpicum et al.: MSCs in kidney transplantation c l i n i ca l t r i a lantibody; NSTEMI, non–ST-elevation myocardial infarction; STEMI, ST-
elevation myocardial infarction.
Figure S2. Individual evolution of control kidney transplant recipients
over 1-year follow-up. DSA, donor-speciﬁc antibody; eGFR, estimated
glomerular ﬁltration rate; KTx, kidney transplantation.
Figure S3. Gating strategy for the identiﬁcation of regulatory T cells
(Tregs). Tregs were deﬁned as CD4þCD25þCD127lowFoxp3þ
lymphocytes. The gating strategy for CD25 was permissive, excluding
only the negative fraction, because the anti-CD25 antibody (CD25-
PeCy7 [BC96, Sony]) shares a common epitope (BC96) with basilix-
imab.99 From this CD25þCD127low population, we selected the
Foxp3-positive fraction.
Figure S4. Flow cytometry of the intracellular expression of Foxp3
and Ki-67 within each regulatory T-cell (Treg) subsets. Tregs were
deﬁned as CD4þCD25þCD127lowFoxp3þ. Tregs were divided into
naive (CD45RAþHLA-DR), resting (CD45RAHLA-DR), and activated
effector (CD45RAHLA-DRþ) cells. (A) Expression of Foxp3 in Treg
subpopulations. The left axis represents the mean ﬂuorescence in-
tensity (MFI) of Foxp3. (B) Expression of Ki-67 in Treg subpopulations.
**P # 0.01, ***P # 0.001.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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